Exelixis falls as US FDA extends cancer drug review
11/09/2026 13:06
BUZZ-Exelixis falls as US FDA extends cancer drug review ** Shares of drug maker Exelixis EXEL.O fall 3.3% to $55.52 premarket
** Co says the U.S. FDA extended the review of its experimental colorectal cancer drug combination by three months
** Regulator to make its decision by March 3, 2027 after co submitted updated safety and efficacy data that the regulator deemed a major amendment
** Co is seeking approval for the drug zanzalintinib with Roche's ROPC.S immunotherapy Tecentriq
** Tecentriq focuses on treatment of subset of adult patients with metastatic colorectal cancer
** As of last close, stock up 31% YTD, on track for four consecutive years of gains
(Reporting by Anand Gopal in Bengaluru)